title: Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.
abstract: BACKGROUND
  It has been reported that the antiplatelet action becomes attenuated when a proton pump inhibitor is used in combination with clopidogrel.
  
  
  OBJECTIVE
  The effect of an antacid causing platelet aggregation during the administration of clopidogrel was investigated.
  
  
  METHODS
  The subjects consisted of 265 patients with coronary artery disease. Platelet aggregation function testing (light transmittance aggregometry) was conducted while aspirin and clopidogrel 75 mg were taken orally and the minimum concentration of aggregation induction platelet aggregation threshold index was measured. The ADP-PATI, measured with ADP as the inducing substance, was compared and investigated according to the type of concomitantly used antacid.
  
  
  RESULTS
  The results of the ADP-PATI were: control group: 3.47 ± 0.95 μM (N = 67), famotidine group: 3.80 ± 0.52 μM (N = 32), rabeprazole group: 3.43 ± 0.93 μM (N = 87), lansoprazole group: 3.28 ± 1.04 μM (N = 63) and omeprazole group: 3.33 ± 0.81 μM (N = 16). No statistically significant difference was observed regarding the ADP-PATI of respective groups compared to the control group.
  
  
  CONCLUSIONS
  The concomitant use of famotidine, rabeprazole, lansoprazole, and omeprazole did not affect the antiplatelet action of clopidogrel in Japanese patients.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Toyama Prefectural Central Hospital, Nishinagae 2-2-78, Toyama-shi, Toyama, Japan. drnagata@nsknet.or.jp
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nagata
authors.forename: Jyun-ichiro
authors.initials: J
authors.lastname: Inomata
authors.forename: Masaki
authors.initials: M
authors.lastname: Kinoshita
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kurokawa
authors.forename: Isao
authors.initials: I
authors.lastname: Aburadani
authors.forename: Michiro
authors.initials: M
authors.lastname: Maruyama
authors.forename: Kazuo
authors.initials: K
authors.lastname: Usuda
mesh_terms: D000368:Aged; D044466:Asian People; D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects*; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004347:Drug Interactions; D015738:Famotidine / Q000008:administration & dosage*; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010979:Platelet Function Tests; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D006635:Histamine H2 Antagonists; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D015738:Famotidine; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin